Sugi Predict

Sugi Predict / Compounds / SCHEMBL1008435

SCHEMBL1008435

SCHEMBL1008435

O=C(O)Cn1nc(C(F)(F)F)c2c1CCCC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 4/20 1.00
▸ TSHR P16473 3/20 0.97
▸ NPSR1 Q6W5P4 1/20 0.97
▸ GAA P10253 1/20 0.76
▸ ALDH1A1 P00352 1/20 0.69
▸ HTT P42858 1/20 0.69
▸ POLQ O75417 1/20 0.62
▸ TDP1 Q9NUW8 1/20 0.61
▸ MAPT P10636 6/20 0.60
▸ TP53 P04637 1/20 0.60
▸ THRB P10828 1/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15708803 0.98 LMNA (1.00) LMNATSHRNPSR1GAAALDH1A1
SCHEMBL1006167 0.97 LMNA (0.94) LMNATSHRNPSR1GAAALDH1A1
SCHEMBL14487929 0.88 LMNA (0.79) LMNATSHRNPSR1GAAALDH1A1
SCHEMBL20371480 0.87 LMNA (1.00) LMNATSHRNPSR1GAAALDH1A1
SCHEMBL12379943 0.87 LMNA (0.76) LMNATSHRNPSR1GAAALDH1A1
SCHEMBL12361570 0.83 LMNA (0.71) LMNATSHRNPSR1GAAALDH1A1
SCHEMBL1007311 0.83 ALDH1A1 (0.97) LMNATSHRNPSR1GAAALDH1A1
SCHEMBL3451759 0.81 LMNA (0.67) LMNATSHRNPSR1GAAALDH1A1
SCHEMBL14487346 0.81 LMNA (0.67) LMNATSHRNPSR1GAAALDH1A1
SCHEMBL15708209 0.80 LMNA (0.67) LMNATSHRNPSR1GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312567-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
US-20230312567-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-10-05 — — US disclosed
CN-114456228-B Substituted glycine-3, 5-difluorophenylalanine peptide derivative and preparation method and application thereof 山东大学 2023-09-12 — — CN disclosed
US-11680064-B2 Capsid inhibitors for the treatment of HIV GILEAD SCIENCES, INC. (US) 2023-06-20 — — US disclosed
US-11680064-B2 Capsid inhibitors for the treatment of HIV GILEAD SCIENCES, INC. (US) 2023-06-20 — — US disclosed
US-20230038823-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2023-02-09 — — US disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 — — US disclosed
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. 2023-01-12 — — US disclosed
CN-114456228-A Substituted glycine-3, 5-difluorophenylalanine peptide derivative and preparation method and application thereof 山东大学 2022-05-10 — — CN disclosed
EP-3954679-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS Gilead Sciences, Inc. (US) 2022-02-16 — — EP disclosed
EP-2269990-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-01-05 — — EP disclosed
US-7820707-B2 Heterocyclic derivatives N.V. ORGANON (NL) 2010-10-26 — — US disclosed
US-7820707-B2 Heterocyclic derivatives N.V. ORGANON (NL) 2010-10-26 — — US disclosed
US-7820707-B2 Heterocyclic derivatives N.V. ORGANON (NL) 2010-10-26 — — US disclosed
EP-2041124-A1 PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS N.V. Organon (NL) 2009-04-01 — — EP disclosed
US-20080255086-A1 Heterocyclic Derivatives N.V. ORGANON (NL) 2008-10-16 — — US disclosed
US-20080255086-A1 Heterocyclic Derivatives N.V. ORGANON (NL) 2008-10-16 — — US disclosed
US-20080255086-A1 Heterocyclic Derivatives N.V. ORGANON (NL) 2008-10-16 — — US disclosed
WO-2008003452-A1 PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS N.V. ORGANON (NL) 2008-01-10 — — WO disclosed
WO-2008003452-A1 PYRAZOLEALKANAMIDE SUBSTITUTED THIOPHENES AS AMPA POTENTIATORS N.V. ORGANON (NL) 2008-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312567-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV HAVCR2, MAVS, CD4 LMNA 2645/4885TSHR 4881/4885NPSR1 4660/4885
US-20230038823-A1 CAPSID INHIBITORS FOR THE TREATMENT OF HIV HAVCR2, MAVS, CD4 LMNA 2645/4885TSHR 4881/4885NPSR1 4660/4885
US-20080255086-A1 Heterocyclic Derivatives GRIN2C, GRIN3A, GRIN1 LMNA 4311/4885TSHR 535/4885NPSR1 103/4885
US-11680064-B2 Capsid inhibitors for the treatment of HIV HAVCR2, MAVS, CD4 LMNA 2645/4885TSHR 4881/4885NPSR1 4660/4885
US-20230012449-A1 COMPOUNDS FOR THE TREATMENT OF HIV CCR5, NPC1, FURIN LMNA 3182/4885TSHR 4824/4885NPSR1 2832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.